Abstract
The expression of activating transcription factor 5 (ATF5) correlates negatively with patient survival in different types of cancer. ATF5 is important for the survival and proliferation of cancer cells, and can be targeted to selectively trigger cancer cell apoptosis while sparing normal cells. Cell-penetrating peptides combined with a dominant negative ATF5 cargo have recently shown efficacy against brain, breast, melanoma, and prostate cancers.
Keywords:
ATF5; CP-d/n-ATF5; apoptosis; cancer; cell-penetrating peptide; dominant negative.
Copyright © 2017 Elsevier Inc. All rights reserved.
Publication types
-
Research Support, N.I.H., Extramural
MeSH terms
-
Activating Transcription Factors / antagonists & inhibitors*
-
Activating Transcription Factors / genetics
-
Activating Transcription Factors / metabolism
-
Animals
-
Antineoplastic Agents / pharmacology*
-
Antineoplastic Agents / therapeutic use
-
Apoptosis / drug effects*
-
Cell Line, Tumor
-
Cell Proliferation / drug effects
-
Cell Survival / drug effects
-
Cell-Penetrating Peptides / pharmacology*
-
Cell-Penetrating Peptides / therapeutic use
-
Female
-
Gene Expression Regulation, Neoplastic / drug effects*
-
Humans
-
Male
-
Mice
-
Neoplasms / drug therapy*
-
Neoplasms / genetics
-
Rats
-
Recombinant Proteins / pharmacology
-
Recombinant Proteins / therapeutic use
-
Xenograft Model Antitumor Assays
Substances
-
ATF5 protein, human
-
Activating Transcription Factors
-
Antineoplastic Agents
-
Cell-Penetrating Peptides
-
Recombinant Proteins